Biotech unicorn Moderna files for IPO of up to $500M

One of the biotech industry's largest unicorns, Cambridge-based Moderna Therapeutics, is planning to go public with an IPO of as much as $500 million, according to documents filed Friday. Moderna is developing messenger RNA molecules, including cancer vaccines, that executives estimates could impact dozens of diseases. The company currently has 10 drug products in clinical trials and another 11 drugs in preclinical development. The company filed documents with the SEC on Friday t o seek up to…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news